MedicineNews.net - Medical Updates

Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment

The EMA's Committee for Medicinal Products for Human Use ( CHMP ) has recommended the approval of Kadcyla ( Trastuzumab emtansine ) for the adjuvant treatment of adult patients with HER2-positive earl ... read article

Revlimid in combination with Rituximab for the treatment of adult patients with previously treated follicular lymphoma

The European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the approval of Revlimid ( Lenalidomide ) in combination wi ... read article

Mayzent for the treatment of adult patients with active secondary progressive multiple sclerosis: CHMP has granted positive opinion

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion for Mayzent ( Siponimod ) for the treatment of adult patients with s ... read article

Metastatic or unresectable recurrent head and neck squamous cell carcinoma: Keytruda, as monotherapy or in combination with Platinum and 5-Fluorouracil chemotherapy, in patients whose tumors express PD-L1

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has adopted a positive opinion recommending approval of two regimens of Keytruda ( Pembrolizumab ), ... read article

Atezolizumab in combination with Bevacizumab has increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma

The phase III IMbrave150 study, evaluating Atezolizumab ( Tecentriq ) in combination with Bevacizumab ( Avastin ) as a treatment for people with unresectable hepatocellular carcinoma ( HCC ) who have ... read article

Ixekizumab superior to Guselkumab in people with moderate to severe plaque psoriasis

Data were presented at the 5th Annual Maui Derm NP+PA Fall meeting from the phase 4 IXORA-R study, the first head-to-head ( H2H ) study between an IL-17A inhibitor and an IL-23/p19 inhibitor using the ... read article

TRK fusion cancer: updated analysis for Larotrectinib has confirmed high response rate and durable responses over three years in children and adults

Updated clinical data for Larotrectinib ( Vitrakvi ) in adult and pediatric patients with TRK fusion cancer showed a high response rate with an overall response rate ( ORR ) of 79% ( 95% CI: 72–85 ) w ... read article

ATLAS-2M trial: similar efficacy of Cabotegravir and Rilpivirine administered every eight weeks compared to four-week administration

Positive results from global phase III ATLAS-2M study of the investigational, long-acting, injectable, 2-drug regimen ( 2DR ) of Cabotegravir and Rilpivirine for the treatment of HIV were announced. ... read article

Pooled five-year survival results for Nivolumab in previously-treated advanced non-small cell lung cancer patients

Long-term pooled efficacy and safety results from the phase 3 CheckMate -017 and CheckMate -057 studies in patients with previously treated advanced non-small cell lung cancer ( NSCLC ) were announced ... read article

5-year open-label treatment period: data have confirmed long-term efficacy and safety of Erenumab

During the OLTP ( open-label treatment period ), Erenumab ( Aimovig ) was not only able to reduce monthly migraine days, but also decrease the number of days requiring acute migraine-specific medicati ... read article

Adults with relapsing multiple sclerosis: Ponesimod reduces the annual rate of relapse

Results from the phase 3 OPTIMUM study, which evaluated the efficacy and safety of Ponesimod compared to Teriflunomide ( Aubagio ) in adults with relapsing multiple sclerosis were announced. The stud ... read article

Atopic dermatitis: effectiveness and safety of Dupilumab in a real-life French multicenter adult cohort

Dupilumab ( Dupixent ) is the first biologic available to treat atopic dermatitis. Its effectiveness and safety were demonstrated in clinical trials. Researchers sought to assess the effectiveness ... read article

Baricitinib, an oral JAK inhibitor, in combination with topical corticosteroids in adult patients with moderate to severe atopic dermatitis

Baricitinib ( Olumiant ) has met the primary endpoint in BREEZE-AD7, the third pivotal phase 3 trial in the BREEZE-AD program to be completed in 2019. BREEZE-AD7, an investigational study evaluatin ... read article

ELEVATE-TN trial: Acalabrutinib alone or in combination has significantly increased the time patients lived without disease progression

Results from the phase III ELEVATE-TN trial of Acalabrutinib ( Calquence ) in patients with previously-untreated chronic lymphocytic leukaemia ( CLL ), the most common type of leukaemia in adults, wer ... read article

Fingolimod is the first and only disease-modifying therapy with proven superiority versus Glatiramer acetate in relapsing remitting multiple sclerosis

Full data of the ASSESS study, which has evaluated the efficacy of oral, once-daily Fingolimod ( Gilenya ) at 0.5mg and 0.25mg versus once-daily subcutaneous injections of Glatiramer acetate 20mg in r ... read article